Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Allergy Therapeutics's enterprise value is $470.97 Mil.
Allergy Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-47.88 Mil. Therefore, Allergy Therapeutics's EV-to-EBITDA for today is -9.84.
The historical rank and industry rank for Allergy Therapeutics's EV-to-EBITDA or its related term are showing as below:
AGYTF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -36.03 Med: -1.61 Max: 1072.03
Current: -9.85
During the past 13 years, the highest EV-to-EBITDA of Allergy Therapeutics was 1072.03. The lowest was -36.03. And the median was -1.61.
AGYTF's EV-to-EBITDA is ranked worse than 100% of 735
companies
in the Drug Manufacturers industry
Industry Median: 13.3
vs AGYTF: -9.85
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Allergy Therapeutics's PE Ratio (TTM) for today is calculated as:
Allergy Therapeutics's share price for today is $0.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Allergy Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.013.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Allergy Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allergy Therapeutics EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Allergy Therapeutics's EV-to-EBITDA falls into.
Allergy Therapeutics's current Enterprise Value is $470.97 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Allergy Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-47.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allergy Therapeutics (AGYTF) has a EV-to-EBITDA of -9.84 as of Aug. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Allergy Therapeutics. According to the industry distribution chart, Allergy Therapeutics ranks #999999 out of 735 companies in the Drug Manufacturers industry.
Is Allergy Therapeutics' EV-to-EBITDA too high?
Allergy Therapeutics' current EV-to-EBITDA is -9.84. Based on the distribution chart, Allergy Therapeutics ranks #999999 out of 735 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Allergy Therapeutics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Allergy Therapeutics' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allergy Therapeutics ranks #999999 out of 735 companies for EV-to-EBITDA. This places Allergy Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 13.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.30, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Allergy Therapeutics. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allergy Therapeutics's current EV-to-EBITDA is -9.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (AGYTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $0.15 — trading 400% above its estimated fair value. The current EV-to-EBITDA is -9.84. Allergy Therapeutics' overall GF Score™ is 24/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Allergy Therapeutics (AGYTF), the current EV-to-EBITDA is -9.84 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allergy Therapeutics (AGYTF) Overvalued in 2026?
Based on GuruFocus' analysis, Allergy Therapeutics stock appears to be overvalued.
The current stock price of $0.15 is trading 400% above its estimated GF Value™ of $0.03.
GuruFocus considers Allergy Therapeutics to be Significantly Overvalued.
Key valuation signals for AGYTF:
EV-to-EBITDA: -9.84
GF Value™: $0.03 vs. price of $0.15 (400% above fair value)
No single metric tells the full story. See the AGYTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
24GF Score
Get the complete analysis for AGYTF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGYTF has been successfully added to your 
